bioMerieux (OTCMKTS:BMXMF) Given Consensus Recommendation of “Reduce” by Analysts

bioMerieux (OTCMKTS:BMXMF – Get Free Report) has been given an average recommendation of “Reduce” by the six ratings firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating and four have assigned a hold rating to the company.

Several research firms have recently issued reports on BMXMF. Piper Sandler initiated coverage on shares of bioMerieux in a report on Thursday, June 11th. They set a “neutral” rating on the stock. UBS Group downgraded bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Zacks Research lowered bioMerieux from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Finally, Morgan Stanley lowered bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday, June 23rd.

Get bioMerieux alerts:

Get Our Latest Analysis on BMXMF

bioMerieux Trading Down 0.9%

Shares of BMXMF stock opened at $86.11 on Friday. bioMerieux has a 1 year low of $77.00 and a 1 year high of $138.15. The firm’s fifty day simple moving average is $81.55 and its 200 day simple moving average is $91.74. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08.

About bioMerieux

(Get Free Report)

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.

See Also

• Five stocks we like better than bioMerieux
• Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
• Is Duolingo the Next Netflix-Style Comeback Story?
• GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
• GTA VI’s Console Problem Isn’t Take-Two’s Problem

Receive News & Ratings for bioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.